| Primary | Percent of Subjects That Achieved Controlled Serum Phosphorous Levels on Calcium-based Phosphate Binder Therapy | Phosphorous levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous of 3.5-5.5 mg/dL. | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | 95% Confidence Interval | percentage of subjects | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Calcium-based Phosphate Binder Therapy | The percent of subjects that achieved the serum phosphate KDOQI target on previous calcium-based phosphate binder therapy of >=3 months of treatment prior to receiving lanthanum carbonate treatment. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Secondary | Percent of Subjects That Achieved Controlled Serum Calcium Levels on Calcium-based Phosphate Binder Therapy | Calcium levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium of 8.4-9.5 mg/dL. | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | 95% Confidence Interval | percentage of subjects | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Calcium-based Phosphate Binder Therapy | The percent of subjects that achieved the serum calcium KDOQI target on previous calcium-based phosphate binder therapy for >=3 months prior to receiving lanthanum carbonate treatment. |
| |
| Secondary | Percent of Subjects That Achieved Controlled Serum Calcium Levels on Lanthanum Carbonate Therapy | Calcium levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium of 8.4-9.5 mg/dL. | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | 95% Confidence Interval | percentage of subjects | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | The percent of subjects that achieved the serum calcium KDOQI target on lanthanum carbonate after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| |
| Secondary | Percent of Subjects That Achieved Controlled Serum Calcium-Phosphorous Product Levels on Calcium-based Phosphate Binder Therapy | Calcium-phosphorous product levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium-phosphorous product of <55 mg^2/dL^2. | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | 95% Confidence Interval | percentage of subjects | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Calcium-based Phosphate Binder Therapy | The percent of subjects that achieved the serum calcium-phosphorous product KDOQI target on previous calcium-based phosphate binder therapy for >=3 months prior to receiving lanthanum carbonate treatment. |
| |
| Secondary | Percent of Subjects That Achieved Controlled Serum Calcium-Phosphorous Product Levels on Lanthanum Carbonate Therapy | Calcium-phosphorous product levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium-phosphorous product of <55 mg^2/dL^2. | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | 95% Confidence Interval | percentage of subjects | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | The percent of subjects that achieved the serum calcium-phosphorous product levels KDOQI target on lanthanum carbonate after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| |
| Secondary | Percent of Subjects That Maintained Control of Serum Phosphorous Levels on Lanthanum Carbonate | Phosphorous levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous of 3.5-5.5 mg/dL. | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | | percentage of subjects | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | The percent of subjects that maintained the serum phosphorous KDOQI target on lanthanum carbonate. |
| |
| Secondary | Percent of Subjects That Maintained Control of Serum Calcium Levels on Lanthanum Carbonate | Calcium levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium of 8.4-9.5 mg/dL. | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | | percentage of subjects | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | The percent of subjects that maintained the serum calcium KDOQI target on lanthanum carbonate. |
| |
| Secondary | Percent of Subjects That Maintained Control of Serum Calcium-Phosphorous Product Levels on Lanthanum Carbonate Therapy | Calcium-phosphorous product levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum calcium-phosphorous product of <55 mg^2/dL^2. | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | | percentage of subjects | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | The percent of subjects that maintained the serum calcium-phosphorous product KDOQI target on lanthanum carbonate. |
| |
| Primary | Percent of Subjects That Achieved Controlled Serum Phosphorous Levels on Lanthanum Carbonate | Phosphorous levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous of 3.5-5.5 mg/dL. | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | 95% Confidence Interval | percentage of subjects | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | The percent of subjects that achieved the serum phosphate KDOQI target on lanthanum carbonate after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| |
| Secondary | Percent of Subjects That Maintained Control of Intact Parathyroid Hormone (iPTH) Levels on Lanthanum Carbonate Therapy | iPTH levels are controlled if they meet the Kidney Disease Outcomes Quality Initiative (KDOQI) target for iPTH of 150-300 pg/mL | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | | percentage of subjects | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | The percent of subjects that maintained the iPTH KDOQI target on lanthanum carbonate. |
| |
| Secondary | Percent Change From Baseline in Phosphorous Levels at 12 Months | | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Mean | Standard Deviation | percent change in phosphorous levels | | Baseline and 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| | |
| Secondary | Percent Change From Baseline in Calcium Levels at 12 Months | | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Mean | Standard Deviation | percent change in calcium levels | | Baseline and 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| | |
| Secondary | Percent Change From Baseline in Calcium-Phosphorous Product Levels at 12 Months | | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Mean | Standard Deviation | percent change in calcium-phosphorous | | Baseline and 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| | |
| Secondary | Percent Change From Baseline in iPTH Levels at 12 Months | | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Mean | Standard Deviation | percent change in iPTH levels | | Baseline and 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| | |
| Secondary | Percent Change From Baseline in 25-Hydroxy Vitamin D Levels at 12 Months | | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. Note that there are a high number of missing values (n=36) for this outcome which does not allow for any meaningful comparison. | Posted | | Mean | Standard Deviation | percent change in vitamin D | | Baseline and 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| |
| Secondary | Percent Change From Baseline in 1,25-Hydroxy Vitamin D Levels at 12 Months | | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. Note that there are a high number of missing values (n=38) for this outcome which does not allow for any meaningful comparison. | Posted | | Mean | Standard Deviation | percent change in vitamin D | | Baseline and 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| |
| Secondary | Percent of Subjects With Hypocalcemic Events on Calcium-based Phosphate Binder Therapy | Hypocalcemia is defined as serum calcium levels below 8.02 mg/dL | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | | percentage of subjects | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Calcium-based Phosphate Binder Therapy | Calcium-based phosphate binder therapy of >=3 months of treatment. |
| |
| Secondary | Percent of Subjects With Hypocalcemic Events on Lanthanum Carbonate | Hypocalcemia is defined as serum calcium levels below 8.02 mg/dL | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | | percentage of subjects | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| |
| Secondary | Percent of Subjects With Hypercalcemic Events on Calcium-based Phosphate Binder Therapy | Hypercalcemia is defined as total serum calcium level above 11.22 mg/dL. | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | | percentage of subjects | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Calcium-based Phosphate Binder Therapy | Calcium-based phosphate binder therapy for >=3 months prior. |
| |
| Secondary | Percent of Subjects With Hypercalcemic Events on Lanthanum Carbonate | Hypercalcemia defined as total serum calcium above 11.22 mg/dL | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Number | | percentage of subjects | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| |
| Secondary | Change From Baseline in Vitamin D Dose at 12 Months | | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Mean | Standard Deviation | ng | | Baseline and 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| | |
| Secondary | Change From Baseline in Mean Total Daily Dose of Calcium at 12 Months | | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior calcium-based phosphate binder therapy. | Posted | | Mean | Standard Deviation | mg | | Baseline and 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| | |
| Secondary | Number of Tablets Per Day | | Full Analysis Set included subjects of the Safety Analysis Set who had values for serum phosphorous, serum calcium, and intact parathyroid hormone (iPTH) while on prior | Posted | | Mean | Standard Deviation | Number of Tablets | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | Lanthanum Carbonate | Lanthanum carbonate therapy after previous calcium-based phosphate binder therapy treatment for >=3 months. |
| | |